Today: 18 July 2026
Goldman Sachs stock falls after Apple Card handoff report — here’s what investors watch next
7 January 2026
2 mins read

Goldman Sachs stock falls after Apple Card handoff report — here’s what investors watch next

New York, Jan 7, 2026, 17:18 EST — After-hours

  • Goldman shares slid after-hours after a report JPMorgan struck a deal to take over Apple Card
  • The portfolio is about $20 billion; Goldman is expected to sell the balances at a discount of more than $1 billion
  • Attention now shifts to Goldman’s Jan. 15 results for any consumer-exit costs and the tone on dealmaking

Goldman Sachs shares fell 1.7% to $941.02 in after-hours trading on Wednesday after the Wall Street Journal reported JPMorgan Chase had reached a deal to take over Apple’s credit-card program from the Wall Street bank. The Journal said the Apple Card book totals about $20 billion and that Goldman is expected to offload the balances at a discount of more than $1 billion.

The report puts a price tag — at least on paper — on Goldman’s pullback from consumer banking. Losing Apple also clears a high-profile tie-up that had become shorthand for that push, fair or not.

Timing is part of the story. Goldman is scheduled to report fourth-quarter results on Jan. 15, before U.S. markets open, and investors will be listening for how fast the bank can finish shrinking consumer exposures and what it means for 2026 returns.

Across Wall Street, analysts expect a strong quarter for bank profits on higher investment banking fees as mergers and acquisitions (M&A) — mergers and acquisitions — picked up. Stephen Biggar, a banking analyst at Argus Research, said the quarter was “a perfect recipe” for investment banking revenue, while LSEG estimates point to a near 4.9% fall in Goldman’s earnings per share, or EPS, from a year earlier; Morningstar’s Sean Dunlop called inflation “the biggest variable” heading into results. Reuters

Goldman’s deal franchise has had a better headline lately. The bank topped global M&A rankings in 2025 with $1.48 trillion in deals advised, and its global co-head of M&A Stephan Feldgoise called it an “extraordinary M&A market” in the firm’s 2026 outlook. JPMorgan led the broader investment-banking fee table at $10.1 billion, versus $8.9 billion for Goldman, LSEG data showed. Reuters

In another window into trading conditions ahead of earnings, Goldman’s prime brokerage note to clients said hedge funds ran up leverage late last year, with gross leverage in its overall prime book rising to 292.8% in December. Leverage — borrowed money used to amplify positions — can lift volumes when it’s rising, and it can cut both ways when markets snap back.

Wednesday’s broader tape was messy. Markets started strong, then faded after mixed U.S. employment data, and investors were looking ahead to Friday’s December payrolls and unemployment report for a cleaner read on the jobs backdrop.

But the Apple Card transfer is not a clean break yet. The handoff is expected to take time, and the final discount — and any knock-on costs tied to exiting the partnership — could still shift, especially if credit performance changes or the portfolio sale proves harder to place.

For traders, the near-term map is simple: Wednesday’s $934–$960 range is now the first band to watch, with the next major catalyst Goldman’s earnings report due Jan. 15 before the bell.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • SELLAS Life Sciences Jumps on Phase 3 Trial Hopes; High Valuation Poses Questions
    July 18, 2026, 2:52 AM EDT. SELLAS Life Sciences Group (SLS) gained 70% over the last month and is up 203% year-to-date, fueled by rising expectations about Phase 3 results for galinpepimut-S in acute myeloid leukemia. Shares recently traded at $13.19 with a price-to-book ratio of 24.1x, well above both the peer average of 9.1x and the biotechnology sector average of 2.6x, putting the stock at a rich valuation. The premium reflects investor confidence even as SELLAS remains unprofitable and posts negative return on equity. Final trial data offers a key upcoming catalyst, but significant risks persist due to the binary outcome of clinical studies and the absence of current revenue. Investors are urged to consider these factors in line with their individual risk profiles.
Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window
Previous Story

Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window

Oracle stock slips after UBS says junk-rating fears look overdone as AI debt grows
Next Story

Oracle stock slips after UBS says junk-rating fears look overdone as AI debt grows

Go toTop